Pharmacotherapy: ACCORD Blood Pressure and ACCORD Lipid: How low can we go?

Nature Reviews Endocrinology

Volumn 6, Issue 9, 2010, Pages 483-484

  Glandt, Mariela ^a   Raz, Itamar ^b  

^a BRONX LEBANON HOSPITAL CENTER   (United States)

^b HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL; VALSARTAN;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CREATININE BLOOD LEVEL; DYSLIPIDEMIA; HUMAN; HYPOKALEMIA; HYPOTENSION; LIPID BLOOD LEVEL; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK REDUCTION; SHORT SURVEY; SIDE EFFECT; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOWN-REGULATION; DRUG COMBINATIONS; DRUG THERAPY; HUMANS; HYPERLIPIDEMIAS; HYPERTENSION; HYPOLIPIDEMIC AGENTS; LIPIDS; MIDDLE AGED;

EID: 77955865521     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2010.128     Document Type: Short Survey

References (10)

1. The ACCORD study Group. effects of intensive blood-pressure control in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1575-1585 (2010).
2. The ACCORD study Group. effects of combination lipid therapy in type 2 diabetes mellitus. N. Engl. J. Med. 362, 1563-1574 (2010).
3. [no authors listed] Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 288, 2981-2997 (2002).
4. Hansson, L. et al. effects of intensive bloodpressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet 351, 1755-1762 (1998). (Pubitemid 28269185)
5. Patel, A. et al. effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADvAnCe trial): a randomized controlled trial. Lancet 370, 829-840 (2007).
6. The nAviGATOR study Group. effect of valsartan on the incidence of diabetes and cardiovascular events. N. Engl. J. Med. 362, 1477-1490 (2010).
7. Cooper-Dehoff, R. M. The invesT trial. Presented at the American College of Cardiology Congress (2010).
8. Keech, A. et al. effects of long-term fenofibrate therapy on cardiovascular events in 9,795 people with type 2 diabetes mellitus (the FieLD study): randomised controlled trial. Lancet 366, 1849-1861 (2005).
9. Mannien, v. et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart study: implications for treatment. Circulation 85, 37-45 (1992).
10. [no authors listed] secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate infarction Prevention (BiP) study. Circulation 102, 21-27 (2000).